Published in Mol Cancer Ther on October 14, 2013
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget (2014) 0.89
Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative and anti-apoptotic bioactivities. Exp Ther Med (2014) 0.87
Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia. Oncotarget (2016) 0.75
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer (2005) 5.83
Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med (1997) 5.53
Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol (2004) 5.29
A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem (1997) 5.23
Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem (2002) 4.54
Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs (1999) 4.32
Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A (1999) 3.85
VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol (2001) 2.80
A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A (1992) 2.76
Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 2.51
Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res (2002) 2.11
Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol Cell Biol (2006) 2.03
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99
Imaging the production of singlet oxygen in vivo using a new fluorescent sensor, Singlet Oxygen Sensor Green. J Exp Bot (2006) 1.92
Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol (2000) 1.76
Mitochondria, oxygen free radicals, and apoptosis. Am J Med Genet (2001) 1.61
The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res (2003) 1.58
Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene (2004) 1.57
Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods (2002) 1.56
The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc Natl Acad Sci U S A (2006) 1.54
Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem (2004) 1.52
2,7-dichlorofluorescin oxidation and reactive oxygen species: what does it measure? Cell Biol Int (2000) 1.29
Ultrasteep voltage dependence in a membrane channel. Proc Natl Acad Sci U S A (1987) 1.22
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood (2001) 1.22
Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther (2002) 1.19
The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun (1999) 1.08
Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol (2006) 1.06
The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand Suppl (1992) 1.02
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol (2001) 0.93
Does cancer therapy trigger cell suicide? Science (1999) 0.92
Disulfiram is a potent inhibitor of proteases of the caspase family. Chem Res Toxicol (1997) 0.90
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin (2005) 0.89
Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol (2002) 0.87
Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J Gastroenterol Hepatol (2005) 0.86
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. J Biol Chem (2007) 0.85
Update on combined-modality treatment options for pancreatic cancer. Oncology (Williston Park) (2003) 0.83
Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas (2003) 0.83
Protein S-glutathionylation and platelet anti-aggregating activity of disulfiram. Biochem Pharmacol (2006) 0.80
Effect of copper and disulfiram combination therapy on the macular mouse, a model of Menkes disease. J Trace Elem Med Biol (2012) 0.79
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Pancreatic cancer and thromboembolic disease. Lancet Oncol (2004) 2.10
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol (2007) 2.09
Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res (2010) 1.92
PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90
Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: a population-based, cross-sectional study. Am J Epidemiol (2006) 1.66
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63
Case report: Paenibacillus thiaminolyticus: a new cause of human infection, inducing bacteremia in a patient on hemodialysis. Ann Clin Lab Sci (2008) 1.57
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett (2006) 1.46
Language matters: "sometimes we withdraw treatment but we never withdraw care". J Palliat Med (2007) 1.45
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol (2006) 1.28
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol (2013) 1.28
Steel dust in the New York City subway system as a source of manganese, chromium, and iron exposures for transit workers. J Urban Health (2005) 1.26
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol (2009) 1.24
MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res (2004) 1.21
Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol (2003) 1.19
Extranodal Rosai-Dorfman disease arising in the right atrium: a case report with literature review. Int J Surg Pathol (2011) 1.19
Priorities for development of research methods in occupational cancer. Environ Health Perspect (2003) 1.15
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery (2011) 1.14
High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis (2002) 1.13
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer (2008) 1.13
Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem (2004) 1.11
LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res (2003) 1.11
Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget (2011) 1.09
Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality. J Invest Dermatol (2010) 1.09
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett (2006) 1.09
Susceptibility to arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett (2003) 1.07
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene (2003) 1.06
Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst (2003) 1.05
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer (2008) 1.05
Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg (2009) 1.04
Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships. J Med Chem (2011) 1.03
Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther (2013) 1.02
Airborne particulate metals in the New York City subway: a pilot study to assess the potential for health impacts. Environ Res (2010) 1.01
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res (2003) 1.00
RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg (2011) 1.00
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res (2013) 1.00
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary (2011) 0.98
Streptococcus gallolyticus subspecies pasteurianus (biotype II/2), a newly reported cause of adult meningitis. J Clin Microbiol (2010) 0.98
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94
A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. Biochem Pharmacol (2002) 0.92
Defective human MutY phosphorylation exists in colorectal cancer cell lines with wild-type MutY alleles. J Biol Chem (2003) 0.91
Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck (2009) 0.91
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci U S A (2007) 0.91
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg (2007) 0.91
XRCC1 polymorphisms and breast cancer risk from the New York Site of the Breast Cancer Family Registry: A family-based case-control study. J Carcinog (2010) 0.90
NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry (2004) 0.90
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2008) 0.89
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther (2005) 0.89
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol (2007) 0.89
The intensity and frequency of moral distress among different healthcare disciplines. J Clin Ethics (2013) 0.89
RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium. Pancreas (2005) 0.88
Cost savings from palliative care teams and guidance for a financially viable palliative care program. Health Serv Res (2014) 0.88
Optimal molecular profiling of tissue and tissue components: defining the best processing and microdissection methods for biomedical applications. Mol Biotechnol (2005) 0.87
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.87
Acid-base effects on intestinal Cl- absorption and vesicular trafficking. Am J Physiol Cell Physiol (2003) 0.87
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Mol Cancer Ther (2006) 0.86
Association of candidate genes with nonsyndromic clefts in Honduran and Colombian populations. Laryngoscope (2012) 0.86
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer (2006) 0.85
Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun (2002) 0.85
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. J Biol Chem (2007) 0.85
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol (2006) 0.84
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery (2014) 0.84
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clin Cancer Res (2002) 0.84
Association of common variants, not rare mutations, in IRF6 with nonsyndromic clefts in a Honduran population. Laryngoscope (2011) 0.83
Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis. Cancer Biol Ther (2010) 0.83
FHIT mRNA and protein expression in hepatocellular carcinoma. Mod Pathol (2004) 0.83
Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study. Neurosurgery (2011) 0.83
Novel IRF6 mutations in Honduran Van der Woude syndrome patients. Mol Med Rep (2011) 0.83
Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells. Int J Cancer (2005) 0.83
Association between the ras p21 oncoprotein in blood samples and breast cancer. Cancer Lett (2002) 0.83
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev (2013) 0.82
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma (2003) 0.82
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A (2010) 0.81